Research Article
Significant Changes in Plasma Alpha-Synuclein and Beta-Synuclein Levels in Male Children with Autism Spectrum Disorder
Table 1
Demographic and clinical features and plasma α-synuclein and β-synuclein levels of the ASD patients and controls.
| | | Controls () | ASD patients | | All ASD patients () | PDD-NOS () | Autism () |
| | Age (mean ± SD) | | | | | | Nonverbal IQ (mean ± SD) | ND | | | | | Vineland test [ (%)] | ND | | | | | Severe deficit | | 1 (2.56) | 0 (0) | 1 (4) | | Moderate deficit | | 21 (53.85) | 9 (64.29) | 12 (48) | | Mild deficit | | 16 (41.03) | 4 (28.57) | 12 (48) | | Adequate | | 1 (2.56) | 1 (7.14) | 0 (0) | | Plasma α-synuclein (ng/mL) | | | | | | Mean ± SD | | | | | | Range (95% CI) | 22.39–36.56 | 8.73–12.92 | 6.45–10.85 | 9.01–15.07 | | Plasma β-synuclein (ng/mL) | | | | | | Mean ± SD | | | | | | Range (95% CI) | 1151.79–1286.52 | 1292.24–1396.14 | 1240.33–1398.05 | 1286.75–1429.69 |
|
|
ASD: autism spectrum disorder, PDD-NOS: pervasive developmental disorder-not otherwise specified, IQ: intelligence quotient, CI: confidence interval, and ND: not done; compared to controls, compared to controls, and compared to PDD-NOS group. |
